A Prospective, Multi-center, Single-arm, Clinical Investigation of the Safety and Performance of the Sentio System in Users With Mixed/Conductive Hearing Losses and Single Sided Deafness
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 51
- 试验地点
- 12
- 主要终点
- Demonstrate that the Sentio system improves hearing on the implanted ear.
研究概览
简要总结
Prospective, open label, single-arm, multi-centre investigation, designed to follow clinical practice for Sentio bone conduction devices in 50 subjects, during 10 clinical visits, and 24 months follow-up.
详细描述
The investigation is a 24-months multinational, multicentre, prospective, open label, single arm investigation on the Sentio system. The purpose of this investigation is to evaluate safety and performance three months after implantation of the new Sentio system. In addition, safety will be analysed six months after implantation, and long-term safety and performance will be evaluated over a 24-month follow-up period. The endpoints chosen, together with applicable measurements, are commonly used, both in the clinical setting as well as in bone anchored hearing research as shown in the scientific literature covering this area. That is, the primary objectives of this study is to demonstrate that the Sentio system improves hearing and speech recognition on the implanted ear. Secondary objectives includes investigation of hearing improvement, speech intelligibility, patient satisfaction, and quality of life. The study also aims to evaluate the safety profile of the Sentio system in terms of the occurrence of adverse events and serious adverse events related to the device.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form
- •Adult subjects (18 years or older)
- •Subjects with 3.
- •conductive or mixed hearing losses with pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2 and 3 kHz) of the indicated ear better than or equal to 45 dB HL.
- •OR subjects who have a profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e. SSD). The pure tone average (PTA) air conduction (AC) threshold of the hearing ear should then be better than or equal to 20 dB HL (measured at 0.5, 1, 2 and 3 kHz) 3.
- •OR subjects who are indicated for an air-conduction contralateral routing of signals (ACCROS) hearing aid, but who for some reason cannot or will not use an AC CROS.
- •Fluent in local language
- •Subjects who have the ability and are willing to follow investigational procedures/requirements, e.g. to complete quality of life scales.
排除标准
- •Inability to undergo general or local anesthesia
- •Prior implantation with percutaneous device or middle ear implant on the side to be implanted
- •Known medical conditions that contraindicate undergoing surgery as judged by the investigator
- •Untreated ongoing middle ear infection at the time of surgery
- •Known insufficient bone quality/quantity/depth or skull size (scull abnormalities) for implantation of a Sentio Ti Implant
- •Known or suspected contact allergy to silicone or other material used in the Sentio system.
- •Known condition that could jeopardize wound healing and skin condition e.g. uncontrolled diabetes over time as judged by the investigator.
- •Known skin or scalp conditions that may preclude attachment or interfere with the usage of the sound processor.
- •Known retro cochlear pathology and auditory processing disorders that may have an impact on the outcome of the investigation
- •Any other known condition that the investigator determines could interfere with compliance or investigation assessments.
- •Use of ototoxic drugs that could be harmful to the hearing, as judged by the investigator.
- •Subject that has received radiotherapy in the area of implantation or is planned for such radiotherapy or similar during the investigation period.
- •For bilateral asymmetric candidates, subject already treated with a bone-anchored hearing solution on the side with the best bone conduction thresholds
- •Known chronic or non-revisable vestibular or balance disorder
- •Known abnormally progressive hearing loss
- •For conductive and mixed losses: evidence that hearing loss is retro-cochlear or of central origin
- •Participation in another clinical investigation with pharmaceuticals and/or devices which might cause interference with investigation participation.
- •Use of active implantable or body worn device that for medical reasons cannot be removed or discontinued, such as implantable cardiac pacemakers, defibrillators, or neurostimulators.
- •Known need for frequent MRI investigations for follow-up of other diseases.
- •Any subject that according to the Declaration of Helsinki is deemed unsuitable for investigation enrolment.
结局指标
主要结局
Demonstrate that the Sentio system improves hearing on the implanted ear.
时间窗: 3 months post-surgery
Functional gain with Sentio, i.e. the difference between preoperative unaided and aided sound field thresholds on the implanted ear.
Demonstrate that the Sentio system provides patients with improved speech recognition on the implanted ear.
时间窗: 3 months post-surgery
Difference in speech recognition score in percent between pre-operative unaided condition and aided with Sentio, measured in quiet on the implanted ear.
次要结局
- Thorough assessment of performance (functional gain, effective gain, speech recognition), satisfaction, usability, comfort and health-related quality of life.(3-24 months post-surgery)